• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本肝胆胰外科专家和指导医师对肝细胞癌手术适应证的问卷调查

Questionnaire survey of Japanese board-certified expert hepatobiliary and pancreatic surgeons and instructors on the surgical indications for hepatocellular carcinoma.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan.

Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan.

出版信息

J Hepatobiliary Pancreat Sci. 2024 Mar;31(3):143-151. doi: 10.1002/jhbp.1408. Epub 2023 Dec 26.

DOI:10.1002/jhbp.1408
PMID:38148501
Abstract

BACKGROUND

Recent advancements in systemic therapy for hepatocellular carcinoma (HCC) necessitate the establishment of resectability criteria for advanced HCC.

METHODS

A questionnaire survey sought to clarify the perspectives of Japanese expert hepatobiliary surgeons regarding surgical indications for HCC. Thirty-one questions were used to determine when surgery is strongly recommended (resectable: R) or not recommended (unresectable: UR).

RESULTS

A total of 351 responses were obtained. While 64.7% of the respondents considered solitary tumors as being R, irrespective of size, opinions diverged on the upper limit of the number of tumors/tumor size for R: (1) up to three nodules with no size limit (27.9%), (2) up to three nodules ≤5 cm in diameter each (21.4%) and (3) up to three nodules ≤3 cm in diameter each (19.4%). Vp1, Vp2, Vp3, and Vp4 were considered as being R by 90.9%, 70.7%, 39.0%, and 8.0% of respondents, respectively. Half of the respondents indicated they would consider resection even for cases with extrahepatic spread under limited conditions.

CONCLUSIONS

The current views of Japanese expert surgeons on the resectability criteria for HCC were clarified for the first time. The findings could serve as a basis for preparing expert consensus statements on the resectability criteria for HCC.

摘要

背景

肝细胞癌(HCC)的系统治疗最近取得了进展,因此需要为晚期 HCC 建立可切除性标准。

方法

一项问卷调查旨在阐明日本专家肝胆外科医生对 HCC 手术适应证的看法。使用 31 个问题来确定何时强烈建议(可切除:R)或不建议(不可切除:UR)手术。

结果

共获得 351 份回复。尽管 64.7%的受访者认为单发肿瘤无论大小均为 R,但对于 R 的肿瘤数量/肿瘤大小的上限存在不同意见:(1)无大小限制的三个结节(27.9%),(2)每个结节最大直径不超过 5cm(21.4%)和(3)每个结节最大直径不超过 3cm(19.4%)。Vp1、Vp2、Vp3 和 Vp4 分别被 90.9%、70.7%、39.0%和 8.0%的受访者认为是 R。半数受访者表示,即使在有限条件下存在肝外扩散,他们也会考虑进行手术切除。

结论

首次明确了日本专家外科医生对 HCC 可切除性标准的当前看法。这些发现可以为 HCC 可切除性标准的专家共识声明的制定提供依据。

相似文献

1
Questionnaire survey of Japanese board-certified expert hepatobiliary and pancreatic surgeons and instructors on the surgical indications for hepatocellular carcinoma.日本肝胆胰外科专家和指导医师对肝细胞癌手术适应证的问卷调查
J Hepatobiliary Pancreat Sci. 2024 Mar;31(3):143-151. doi: 10.1002/jhbp.1408. Epub 2023 Dec 26.
2
Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature.肝细胞癌的可切除性:单肝胆专科中心333例连续病例的评估及文献系统综述
Hepatogastroenterology. 2006 May-Jun;53(69):322-9.
3
Current status of surgical treatment for hepatocellular carcinoma.
J Med Invest. 2000 Aug;47(3-4):91-100.
4
[The progresses of liver resection for solitary large hepatocellular carcinoma].[孤立性大肝细胞癌肝切除术的进展]
Zhonghua Wai Ke Za Zhi. 2020 Jan 1;58(1):13-16. doi: 10.3760/cma.j.issn.0529-5815.2020.01.004.
5
A Conceptual Classification of Resectability for Hepatocellular Carcinoma.肝癌可切除性的概念分类。
World J Surg. 2023 Mar;47(3):740-748. doi: 10.1007/s00268-022-06803-7. Epub 2022 Oct 26.
6
Expanding Indications for Surgical Resection in Hepatocellular Carcinoma: What is the Evidence?肝细胞癌手术切除适应证的扩展:证据是什么?
Surg Oncol Clin N Am. 2024 Jan;33(1):99-109. doi: 10.1016/j.soc.2023.07.004. Epub 2023 Aug 29.
7
Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.不可切除肝细胞癌的术前全身化疗免疫治疗及序贯切除术
Ann Surg. 2001 Feb;233(2):236-41. doi: 10.1097/00000658-200102000-00013.
8
Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?评估结直肠癌肝转移的可切除性:不同亚专业如何解读相同的数据?
Can J Surg. 2018 Aug;61(4):251-256. doi: 10.1503/cjs.014616.
9
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.可切除、交界可切除和局部进展期胰腺癌新辅助治疗的意见和应用:国际调查和病例简述研究。
BMC Cancer. 2019 Jul 9;19(1):675. doi: 10.1186/s12885-019-5889-5.
10
Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria.米兰标准范围内乙型肝炎病毒相关性肝细胞癌微血管侵犯风险的术前预测列线图。
JAMA Surg. 2016 Apr;151(4):356-63. doi: 10.1001/jamasurg.2015.4257.

引用本文的文献

1
Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.基于临界可切除肝细胞癌肿瘤学可切除标准的肝切除术与全身化疗的预后
Liver Cancer. 2025 Jun 10. doi: 10.1159/000546830.
2
Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?人工智能(AI)在人类癌症中的临床应用:是时候更新肝细胞癌(HCC)管理中的诊断和预测模型了吗?
Diagnostics (Basel). 2025 Jan 22;15(3):252. doi: 10.3390/diagnostics15030252.
3
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023.
新型全身治疗时代肝细胞癌的肿瘤可切除性标准:日本肝癌协会和日本肝胆胰外科学会2023年专家共识声明
Liver Cancer. 2024 Mar 29;13(6):0-10. doi: 10.1159/000538627. eCollection 2024 Dec.
4
Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts.肝细胞癌全身治疗的演变:不断变化的治疗策略与理念
Cancers (Basel). 2024 Jun 28;16(13):2387. doi: 10.3390/cancers16132387.
5
Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma.肝切除在肝细胞癌晚期全身治疗时代的作用。
Glob Health Med. 2024 Jun 30;6(3):170-173. doi: 10.35772/ghm.2024.01002.